New antibody drug takes aim at Hard-to-Treat brain cancers

NCT ID NCT05916313

Recruiting now Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called BI 764532 in 20 adults with a type of brain tumor (glioma) that has a specific marker called DLL3 and hasn't improved with prior treatment. The drug is designed to link cancer cells to immune cells, helping the body fight the tumor. The main goal is to find a safe dose and see if it can be tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 764532 (Obrixtamig), an antibody-like molecule that links cancer cells and immune T-cells
What this could lead to: If it works, this could point toward a new treatment option for people with advanced glioma that hasn't responded to other therapies.
What could go wrong: This is an early, small Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not shrink tumors or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

Contacts and locations

Locations

Cantonal Hospital of Aarau
RECRUITING

Aarau, CH-5001, Switzerland
Erasmus Medisch Centrum-ROTTERDAM-50697
RECRUITING

Rotterdam, 3015 GD, Netherlands
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital del Mar
RECRUITING

Barcelona, 08003, Spain
Klinikum der Universität München AÖR
COMPLETED

München, 81377, Germany
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Salzburg Cancer Research Institute
RECRUITING

Salzburg, 5020, Austria
University Hosp. Zurich
RECRUITING

Zurich, 8901, Switzerland
University Hospital of Lausanne
RECRUITING

Lausanne, 1101, Switzerland
University of California Irvine
RECRUITING

Orange, California, 92868, United States
Universitätsklinikum Frankfurt
RECRUITING

Frankfurt, 60596, Germany
Universitätsklinikum Tübingen
RECRUITING

Tübingen, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.